🔗 Share this article

Given that the US undertakes historic changes to its vaccination recommendations, an unexpected name appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by questioning coronavirus vaccinations during the global health crisis and has zeroed in on potential deaths following COVID-19 vaccination in her brief time at the Food and Drug Administration.

Proposed Overhauls to Childhood Immunization Schedule

Agency leaders planned to announce radical changes to the pediatric immunization program recently, aligning the US with the Danish vaccine program, it is understood – a major change that would put the US at odds with many the world with little proof for benefit. This reveal has been pushed back until the new year.

In place of the top vaccines chief, Dr. Høeg is set to speak at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to run the office this year.

A Shift at the FDA

This interim role could signify a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Høeg has repeatedly called for halting certain pediatric immunization guidelines in the US so as to align more like Denmark, a society with universal health coverage and a population roughly the population of Wisconsin’s.

In her initial public appearances, she has continued to focus on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Background

The appointee has no obvious experience in drug development, oversight or leadership, which has been typical for past heads of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She lacks experience in leading a sizeable institution. She lacks background in pharmaceutical oversight.”

Previous heads of the center would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she lacks the sort of resume that former directors who headed CBER have had.”

The drug center has an vast range of responsibilities at the agency, she stated.

“Everybody just focuses on the new drug program, but the generic drug division clears numerous generic medications. There’s a biologic copycat branch, OTC medication office and more, and all of those have to be supervised,” she noted. “The thing you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a major leadership component to the position, which supervises over 5,000 staff members. “It is a massive management job, if you execute it properly,” she said.

Official Statement and Disputed Programs

Regarding concerns about Dr. Høeg's credentials and whether this appointment indicates greater collaboration among agency officials on immunizations, a press secretary stated that the “questions rely on inaccurate premises”.

“Her experience aligns with the duties of her role,” the spokesperson stated, noting the time Dr. Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s new fast-track approval initiative, a contentious one-day medication authorization process that apparently troubled her predecessors. “By what process are these drugs being picked for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he stated, “the agency appears to be shifting towards laxer rules of most medications, with the exception of immunizations.”

Public Past Work on Immunizations

Concerning immunizations, Høeg has a more established, if problematic, history, some experts said. She released a research paper using unverified crowd-sourced reports to assess the frequency of myocarditis after Covid immunization. She advised the Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccinations are riskier than they are.

Among her “wish list” for the incoming federal leadership encompassed altering regulations for novel immunizations and ending “optional” immunizations, she said post-election on a audio program. At the FDA, Dr. Høeg has reportedly proposed excluding young men from receiving COVID-19 vaccines.

“She’s an complete dogmatist who commences with her conclusions and works backwards to retrofit the science in a extremely disingenuous, fraudulent manner,” Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|